Results 111 to 120 of about 529 (145)

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. [PDF]

J Immunother Cancer
Ghiringhelli F, Kim R, Macarulla T, Moreno I, Abdul Razak A, Rodon Ahnert J, Liao CY, Davis SL, Mahipal A, Marron T, Raimbourg J, Kaplon H, Geronimi J, Harouki N, Rodrigues C, Darcel P, Jakobsen JS, Skartved N, Hald R, Lopez-Ravnborg D, He P, Ianopoulos X, Askoxylakis V, Lakhani N.   +23 more
europepmc   +1 more source

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. [PDF]

J Clin Oncol
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V, ENGOT-en9/LEAP-001 Investigators.   +30 more
europepmc   +1 more source

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. [PDF]

J Clin Oncol
Hamid O, Lewis KD, Weise A, McKean M, Papadopoulos KP, Crown J, Kim TM, Lee DH, Thomas SS, Mehnert J, Kaczmar J, Lakhani NJ, Kim KB, Middleton MR, Rabinowits G, Spira AI, Yushak M, Mehmi I, Fang F, Chen S, Mani J, Jankovic V, Wang F, Fiaschi N, Brennan L, Paccaly A, Masinde S, Salvati M, Fury MG, Kroog G, Lowy I, Gullo G.   +31 more
europepmc   +1 more source

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. [PDF]

Future Oncol
Powles T, Bhatia A, Burtness B, Kogawa T, Nishina T, Nakayama I, Fountzilas C, Castillo DR, McKean M, Meric-Bernstam F, Colombo N, Smithy JW, Fayette J, Chandra S, Sternberg DW, Jin F, Sullivan K, Yueh S, Clinthorne G, Aguilo AE, Kudchadkar R, Hayashi H.   +21 more
europepmc   +1 more source

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. [PDF]

Cancer Res Commun
Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, McKean MA, Emens LA, Saenger YM, Ged Y, Stagg R, Smith S, Whiting CC, Moon A, Prasit P, Jenkins Y, Standifer N, Dubensky TW, Whiting SH, Ulahannan SV.   +19 more
europepmc   +1 more source

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. [PDF]

J Immunother Cancer
Rohrberg KS, Melero I, F Sanmamed M, Muñoz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim HR, Lee DH, Italiano A, Cassier PA, Hiret S, Deva S, Kim TM, Blumenschein GR, Løvendahl Eefsen R, Henick BS, Perro M, Umaña P, Peixoto A, Lauener L, Weber P, Seeber S, Klein C, Higgins B, Guidi M, Kraus D, Mücke M, Heichinger C, Tran VL, Schmid D, Michielin F, Liu T, McIntyre C, Kao H, Codarri Deak L, Markert C, Moreno V.   +38 more
europepmc   +1 more source

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. [PDF]

Clin Cancer Res
Ku G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, Wang Z, Feller L, Girda E, Pan H, Kim S, Deng Y, Deng T, Liu T, Powderly J, Spencer K, Schneider R, Berlin J, Xu CC, Ahlers CM, Liu X, Chung JK, Sabbatini P, Park J, Lim Y, Jeon J, Meng Y, Klempner SJ.   +27 more
europepmc   +1 more source

Chinese ethnic dance therapy: cultural anthropology and health science perspectives on Tujia ethnic dances. [PDF]

Front Psychol
Mao Q, Mastnak W, Guan R.
europepmc   +1 more source

First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A. [PDF]

Clin Cancer Res
Papadopoulos KP, McKean M, Goldoni S, Genvresse I, Garrido MF, Li R, Wilkinson G, Kneip C, Yap TA.   +8 more
europepmc   +1 more source

A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. [PDF]

Front Oncol
Gill D, Cowey CL, Daniels GA, Sommerhalder D, Abdul-Karim R, Kirkwood JM, Kolodney J, Mehmi I, Roberts-Thomson R, Strauss J, Thomas S, Whitman E, Xing Y, McKean M, Collins S, Li C, Saggu G, Chen T, Wang S, Lewis M, Parot X, Johnson M.   +21 more
europepmc   +1 more source